AstraZeneca's Tremelimumab-Imfinzi combo to get US priority review
(Alliance News) - AstraZeneca PLC on Monday announced its candidate for unresectable liver cancer Tremelimumab has been accepted under priority review by the US Food & Drug Administration. Read More